Peptide recovery after injury: what the published evidence supports
Most of the "recovery peptide" conversation rides on animal data. The human-trial story is shorter and more honest.
TL;DR
- Animal research on BPC-157 and TB-500 describes consistent tissue and tendon repair effects.
- Human trial evidence is limited. FDA's final decision on BPC-157 and TB-500 is pending as of September 2026.
- The recovery peptides with the strongest human data sit in growth-hormone deficiency and HIV-related conditions, not sports injury.
What it is
Recovery peptides is a marketing umbrella for compounds proposed to speed healing after soft-tissue injury, surgery, or training stress. The most discussed are BPC-157 (in plain English: "body protection compound 157," a 15-amino-acid peptide originally identified in human gastric juice) and TB-500 (in plain English: a synthetic analog of thymosin beta-4, a protein your body makes that helps cells migrate to wound sites). Growth-hormone peptides — sermorelin, CJC-1295, ipamorelin — are sometimes grouped here for their effects on lean mass and sleep architecture.
How it works
Think of the healing process like a construction site. After an injury, the body sends workers (immune cells), materials (collagen, signaling molecules), and a project manager (cytokines and growth factors). The animal research describes BPC-157 as something that improves the project manager's coordination — more blood vessels to the site (in plain English: angiogenesis), more organized repair-cell migration, faster wound closure (Sikiric et al., Current Pharmaceutical Design, 2018). TB-500 is described as helping cells move toward damaged tissue (Chang et al., J Appl Physiol, 2011). Both descriptions come primarily from rodent studies.
Who asks about it
People come to this question after an injury or surgery and want to know what is real. The honest answer: animal evidence is real, human evidence is thinner, and the regulatory status changed in 2024–2026 in ways that affect access.
What the research says
A 2018 review summarized BPC-157 as having broad effects across rodent injury models while explicitly noting limited human trials (Sikiric et al., 2018). Thymosin beta-4 reviews describe consistent cell-migration effects in animal wound-healing models (Chang et al., 2011). The "recovery peptide" category as marketed runs ahead of what published human trials support today.
What to know before considering it
As of September 2026, FDA has not made a final decision on BPC-157 or TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted separately on each. Both votes were 8 yes, 6 no, and 1 abstention to recommend adding the peptide to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. Any peptide-based recovery plan requires a licensed physician evaluation. Standard recovery fundamentals — protein, sleep, progressive loading, physical therapy — still carry most of the load.
The Halftime POV
The recovery peptide story is the cleanest example of why we read evidence levels carefully. Animal depth is real. Human-trial depth is not yet there. Access depends on regulatory status that is moving. All three things stay true at once.
Related reading:
- BPC-157: 30 years of animal research
- BPC-157 human trials: what has actually been studied
- TB-500 and tissue repair: signal vs noise
FAQ
Q: Do peptides help with injury recovery? A: Animal research on peptides like BPC-157 and TB-500 consistently describes tissue, tendon, and gut repair effects. Large human trials are limited. As of September 2026, FDA has not made a final decision on BPC-157 or TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted separately on each. Both votes were 8 yes, 6 no, and 1 abstention to recommend adding the peptide to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action.
Q: Are BPC-157 and TB-500 legal in 2026? A: FDA removed BPC-157 and TB-500 from Category 2 on April 22, 2026, after their nominations were withdrawn. As of September 14, 2026, neither is in any FDA 503A category or on the 503A bulks list. In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list. As of September 2026, FDA has not made a final decision on BPC-157 or TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted separately on each. Both votes were 8 yes, 6 no, and 1 abstention to recommend adding the peptide to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness.
Q: What recovery effects have human studies? A: Most published peptide recovery data is preclinical. The strongest human-trial recovery evidence in the broader peptide space is in conditions like growth hormone deficiency and HIV-associated muscle wasting — not soft-tissue sports injury.
Disclaimer
As of September 2026, FDA has not made a final decision on BPC-157 or TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted separately on each. Both votes were 8 yes, 6 no, and 1 abstention to recommend adding the peptide to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.
Get started
We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.
Sources
- Sikiric P et al., Current Pharmaceutical Design, 2018 — BPC-157: A Review of Its Pharmacology and Healing Effects
- Chang CH et al., J Appl Physiol, 2011 — The Promoting Effect of BPC-157 on Tendon Healing
This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
Do peptides help with injury recovery?
Animal research on peptides like BPC-157 and TB-500 consistently describes tissue, tendon, and gut repair effects. Large human trials are limited. As of September 2026, FDA has not made a final decision on BPC-157 or TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted separately on each. Both votes were 8 yes, 6 no, and 1 abstention to recommend adding the peptide to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action.
Are BPC-157 and TB-500 legal in 2026?
FDA removed BPC-157 and TB-500 from Category 2 on April 22, 2026, after their nominations were withdrawn. As of September 14, 2026, neither is in any FDA 503A category or on the 503A bulks list. In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list. As of September 2026, FDA has not made a final decision on BPC-157 or TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted separately on each. Both votes were 8 yes, 6 no, and 1 abstention to recommend adding the peptide to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness.
What recovery effects have human studies?
Most published peptide recovery data is preclinical. The strongest human-trial recovery evidence in the broader peptide space is in conditions like growth hormone deficiency and HIV-associated muscle wasting — not soft-tissue sports injury.
Keep reading
A licensed physician reviews your labs and builds your protocol.
Membership from $39/mo, or $390 for the year, including your onboarding panel. Each protocol is its own monthly subscription.